102 related articles for article (PubMed ID: 29212217)
1. TMED2 promotes epithelial ovarian cancer growth.
Shi-Peng G; Chun-Lin C; Huan W; Fan-Liang M; Yong-Ning C; Ya-Di Z; Guang-Ping Z; Ye-Ping C
Oncotarget; 2017 Nov; 8(55):94151-94165. PubMed ID: 29212217
[TBL] [Abstract][Full Text] [Related]
2. SPP1 promotes ovarian cancer progression via Integrin β1/FAK/AKT signaling pathway.
Zeng B; Zhou M; Wu H; Xiong Z
Onco Targets Ther; 2018; 11():1333-1343. PubMed ID: 29559792
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth.
Hu J; Meng Y; Yu T; Hu L; Mao M
Oncotarget; 2015 May; 6(14):12174-87. PubMed ID: 25895127
[TBL] [Abstract][Full Text] [Related]
4. TMED2 promotes glioma tumorigenesis by being involved in EGFR recycling transport.
Sun C; Zhang Y; Wang Z; Chen J; Zhang J; Gu Y
Int J Biol Macromol; 2024 Mar; 262(Pt 2):130055. PubMed ID: 38354922
[TBL] [Abstract][Full Text] [Related]
5. The trafficking protein Tmed2/p24beta(1) is required for morphogenesis of the mouse embryo and placenta.
Jerome-Majewska LA; Achkar T; Luo L; Lupu F; Lacy E
Dev Biol; 2010 May; 341(1):154-66. PubMed ID: 20178780
[TBL] [Abstract][Full Text] [Related]
6. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-133b inhibits proliferation and invasion of ovarian cancer cells through Akt and Erk1/2 inactivation by targeting epidermal growth factor receptor.
Liu X; Li G
Int J Clin Exp Pathol; 2015; 8(9):10605-14. PubMed ID: 26617770
[TBL] [Abstract][Full Text] [Related]
8. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer.
Lin X; Liu J; Hu SF; Hu X
Cancer Manag Res; 2019; 11():2203-2214. PubMed ID: 31114314
[No Abstract] [Full Text] [Related]
10. TMED2/p24β1 is expressed in all gestational stages of human placentas and in choriocarcinoma cell lines.
Zakariyah A; Hou W; Slim R; Jerome-Majewska L
Placenta; 2012 Mar; 33(3):214-9. PubMed ID: 22212250
[TBL] [Abstract][Full Text] [Related]
11. Expression and Importance of TMED2 in Multiple Myeloma Cells.
Ge X; Jiang W; Jiang Y; Lv X; Liu X; Wang X
Cancer Manag Res; 2020; 12():12895-12903. PubMed ID: 33364837
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.
Wu YR; Qi HJ; Deng DF; Luo YY; Yang SL
Tumour Biol; 2016 Sep; 37(9):12061-12070. PubMed ID: 27188433
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-106b promotes pituitary tumor cell proliferation and invasion through PI3K/AKT signaling pathway by targeting PTEN.
Zhou K; Zhang T; Fan Y; Serick ; Du G; Wu P; Geng D
Tumour Biol; 2016 Oct; 37(10):13469-13477. PubMed ID: 27465551
[TBL] [Abstract][Full Text] [Related]
14. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer.
Lu WD; Zuo Y; Xu Z; Zhang M
World J Gastroenterol; 2015 Apr; 21(15):4564-73. PubMed ID: 25914465
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2.
Hou W; Gupta S; Beauchamp MC; Yuan L; Jerome-Majewska LA
PLoS One; 2017; 12(8):e0182995. PubMed ID: 28797121
[TBL] [Abstract][Full Text] [Related]
16. HOTAIR Interacting with MAPK1 Regulates Ovarian Cancer skov3 Cell Proliferation, Migration, and Invasion.
Yiwei T; Hua H; Hui G; Mao M; Xiang L
Med Sci Monit; 2015 Jun; 21():1856-63. PubMed ID: 26117268
[TBL] [Abstract][Full Text] [Related]
17. Role of microRNA 30a targeting insulin receptor substrate 2 in colorectal tumorigenesis.
Zhang Q; Tang Q; Qin D; Yu L; Huang R; Lv G; Zou Z; Jiang XC; Zou C; Liu W; Luo J; Zhao Z; Muhammad S; Wang G; Chen YG; Wang X
Mol Cell Biol; 2015 Mar; 35(6):988-1000. PubMed ID: 25582198
[TBL] [Abstract][Full Text] [Related]
18. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer.
Lu W; Xu Z; Zhang M; Zuo Y
Int J Clin Exp Pathol; 2014; 7(10):7286-96. PubMed ID: 25400827
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor.
Zhao X; Dou W; He L; Liang S; Tie J; Liu C; Li T; Lu Y; Mo P; Shi Y; Wu K; Nie Y; Fan D
Oncogene; 2013 Mar; 32(11):1363-72. PubMed ID: 22614005
[TBL] [Abstract][Full Text] [Related]
20. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Noske A; Kaszubiak A; Weichert W; Sers C; Niesporek S; Koch I; Schaefer B; Sehouli J; Dietel M; Lage H; Denkert C
Cancer Lett; 2007 Feb; 246(1-2):190-200. PubMed ID: 16584837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
